Anticoagulant Reversal Drugs Market is expected to reach US$ 2,276.54 Mn by 2027
                     Anticoagulant Reversal Drugs Market
The anticoagulant 
reversal drugs market is 
expected to reach US$ 
2,276.54 million by 2027 
from US$ 922.55 million 
in 2019; the market is 
estimated to grow at a 
CAGR of 12.6% from 2020 
to 2027.
Current and future Market Scenario
 Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned 
surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. Anticoagulant reversal drugs are used in medical 
conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation 
disorders such as antiphospholipid antibody syndrome and Factor V Leiden. The growth of the anticoagulant reversal drug 
market growth is mainly attributed to the factors such as rising prevalence of atrial fibrillation (AFib) and stroke. However, the 
high cost of anticoagulant reversal drugs is restricting the market growth.
 According to our new market research study on “Anticoagulant Reversal Drugs Market Forecast to 2027 – COVID-19 Impact and 
Global Analysis – by Product, and Distribution channel,” the market is expected to reach US$ 2,276.54 million in 2027 from US$ 
922.55 in 2019; it is estimated to grow at a CAGR of 12.6% from 2020 to 2027. The report highlights trends prevailing in the 
global anticoagulant reversal drugs market, and the factors governing the market growth.
Current and future Market Scenario
 Based on distribution channel, the anticoagulant reversal drugs market is segmented into hospital pharmacies, retail 
pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and is estimated to 
register the highest CAGR in the market during the forecast period. Hospital pharmacies offer complex and specialized 
medicines, which may not be available in a retail pharmacy. It ensures the availability of right medication, in the right dose 
and at the right time. These factors are expected to contribute to the growth of the market during the forecast period.
 The global anticoagulant reversal drugs market growth is mainly attributed to the rising prevalence of atrial fibrillation (AFib) 
and stroke. However, the high cost of anticoagulant reversal drugs is restricting the market growth.
 Boehringer Ingelheim International GmbH; Pfizer Inc; Octapharma AG; Amag Pharmaceuticals, Inc; Fresenius Kabi AG; 
Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals); CSL Limited; China Biologic Products, Inc; Grifols, S.A; and Shanghai 
RAAS Blood Products Co., Ltd are among the key companies in the anticoagulant reversal drugs market.  
Key Findings
Market Insights
Rise in Prevalence of Atrial Fibrillation (AFib)
 Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, 
the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent 
bleeding.
 As per the Centers for Disease Control and Prevention (CDC), in 2018, in the US, AFib was mentioned on around 175,326 
death certificates and was the primary cause of death in about 25,845 of those deaths. Additionally, it has also anticipated 
that 12.1 million people in the US will have AFib by 2030.
 Moreover, according to the European Society of Cardiology (ESC), in 2016, 7.6 million people above 65 years of age in the EU 
had atrial fibrillation and it is expected that the number will increase by 89% to reach 14.4 million by 2060. Similarly, as per 
the Stroke Association: State of the Nation 2017, more than 1 million people in the UK suffer from atrial fibrillation.
Thus such high prevalence of atrial fibrillation across the world is likely to favor the growth of the market.
Key Findings
Product-Based Insights
 Based on product, the anticoagulant reversal drugs market is segmented into prothrombin complex concentrates, vitamin k, 
protamine, tranexamic acid, idarucizumab, and AndeXXa. The prothrombin complex concentrates segment held the largest 
share of the market in 2019; whereas, the AndeXXa segment is estimated to register the highest CAGR in the market during 
the forecast period. Prothrombin complex concentrates are widely used as a reliable and fast alternative to fresh frozen 
plasma and controls excessive bleeding.
Distribution channel-Based Insights
 Based on distribution channel, the anticoagulant reversal drugs market is segmented into hospital pharmacies, retail 
pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2019, and is estimated to 
register the highest CAGR in the market during the forecast period.
Key Findings
Strategic Insights
 Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints 
and product portfolios. Collaboration is one of the major strategies adopted by the anticoagulant reversal drug market 
players to enlarge customer base worldwide, which also permits them to maintain their brand name globally.
 Download PDF Brochure @ https://www.theinsightpartners.com/sample/TIPRE00004954/ 
Key Findings
Market Segments
By Product By Product by Distribution Channel
• Prothrombin Complex • Tranexamic Acid • Hospital Pharmacies
Concentrates • Idarucizumab • Retail Pharmacies
• Vitamin K • AndeXXa • Others
• Protamine
By Geography
North America Asia Pacific South America
• US • China • Brazil
• Canada • India • Argentina
• Mexico • South Korea • Rest of South America
• Japan
Europe • Australia
• Rest of Asia Pacific
• France
• Germany Middle East & Africa
• Italy
• UK • South Africa
• Spain • Saudi Arabia
• Rest of Europe • UAE
• Rest of Middle East and Africa
Leading Players
Company Profiles
• Boehringer Ingelheim International GmbH
• Pfizer Inc
• Octapharma AG
• Amag Pharmaceuticals, Inc
• Fresenius Kabi AG
• Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals)
• CSL Limited
• China Biologic Products, Inc
• Grifols, S.A
• Shanghai RAAS Blood Products Co., Ltd.
  REASONS TO BUY
• Save and reduce time carrying out entry-level research by identifying the growth, size, leading 
players and segments in the anticoagulant reversal drugs market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global 
anticoagulant reversal drugs market, thereby allowing players across the value chain to develop 
effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and 
emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as 
well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security 
interest with respect to client products, segmentation, pricing and distribution.
      Anticoagulant Reversal Drugs Market
        
Access Full Research Report at:
https://www.theinsightpartners.com/reports/anticoagulant-reversal-dru
gs-market/
Thank You! 
Thank You!